Cargando…
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
PURPOSE: To examine and compare patient and oncologist preferences for advanced melanoma treatment attributes and to document their trade-offs for benefits with risks. MATERIALS AND METHODS: A discrete choice experiment (DCE) was conducted among advanced melanoma patients and oncologists. Qualitativ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565374/ https://www.ncbi.nlm.nih.gov/pubmed/28860722 http://dx.doi.org/10.2147/PPA.S140226 |
_version_ | 1783258384132210688 |
---|---|
author | Liu, Frank Xiaoqing Witt, Edward A Ebbinghaus, Scot DiBonaventura Beyer, Grace Shinde, Reshma Basurto, Enrique Joseph, Richard W |
author_facet | Liu, Frank Xiaoqing Witt, Edward A Ebbinghaus, Scot DiBonaventura Beyer, Grace Shinde, Reshma Basurto, Enrique Joseph, Richard W |
author_sort | Liu, Frank Xiaoqing |
collection | PubMed |
description | PURPOSE: To examine and compare patient and oncologist preferences for advanced melanoma treatment attributes and to document their trade-offs for benefits with risks. MATERIALS AND METHODS: A discrete choice experiment (DCE) was conducted among advanced melanoma patients and oncologists. Qualitative pilot testing was used to inform the DCE design. A series of scenarios asked stakeholders to choose between two hypothetical medications, each with seven attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (MDT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3–4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to determine patients’ and oncologists’ choice-based preferences, analysis of variance models were used to estimate the relative importance of attributes, and independent t-tests were used to compare relative importance estimates between stakeholders. RESULTS: In total, 200 patients and 226 oncologists completed the study. OS was most important to patients (33%), followed by AEs (29%) and ORR (25%). For oncologists, AEs were most important (49%), followed by OS (34%) and ORR (12%). An improvement from 55% to 75% in 1-year OS was valued similar in magnitude to a 23% decrease (from 55% to 32%) in likelihood of AEs for oncologists. CONCLUSION: Patients valued OS, AEs, and ORR sequentially as the most important attributes in making a treatment decision, whereas oncologists valued AEs most, followed by OS and ORR. In comparison, patients differed significantly from oncologists on the importance of ORR, AEs, and PFS, but were consistent in OS and the rest of attributes. |
format | Online Article Text |
id | pubmed-5565374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55653742017-08-31 Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment Liu, Frank Xiaoqing Witt, Edward A Ebbinghaus, Scot DiBonaventura Beyer, Grace Shinde, Reshma Basurto, Enrique Joseph, Richard W Patient Prefer Adherence Original Research PURPOSE: To examine and compare patient and oncologist preferences for advanced melanoma treatment attributes and to document their trade-offs for benefits with risks. MATERIALS AND METHODS: A discrete choice experiment (DCE) was conducted among advanced melanoma patients and oncologists. Qualitative pilot testing was used to inform the DCE design. A series of scenarios asked stakeholders to choose between two hypothetical medications, each with seven attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (MDT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3–4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to determine patients’ and oncologists’ choice-based preferences, analysis of variance models were used to estimate the relative importance of attributes, and independent t-tests were used to compare relative importance estimates between stakeholders. RESULTS: In total, 200 patients and 226 oncologists completed the study. OS was most important to patients (33%), followed by AEs (29%) and ORR (25%). For oncologists, AEs were most important (49%), followed by OS (34%) and ORR (12%). An improvement from 55% to 75% in 1-year OS was valued similar in magnitude to a 23% decrease (from 55% to 32%) in likelihood of AEs for oncologists. CONCLUSION: Patients valued OS, AEs, and ORR sequentially as the most important attributes in making a treatment decision, whereas oncologists valued AEs most, followed by OS and ORR. In comparison, patients differed significantly from oncologists on the importance of ORR, AEs, and PFS, but were consistent in OS and the rest of attributes. Dove Medical Press 2017-08-14 /pmc/articles/PMC5565374/ /pubmed/28860722 http://dx.doi.org/10.2147/PPA.S140226 Text en © 2017 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Liu, Frank Xiaoqing Witt, Edward A Ebbinghaus, Scot DiBonaventura Beyer, Grace Shinde, Reshma Basurto, Enrique Joseph, Richard W Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title_full | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title_fullStr | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title_full_unstemmed | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title_short | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
title_sort | patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565374/ https://www.ncbi.nlm.nih.gov/pubmed/28860722 http://dx.doi.org/10.2147/PPA.S140226 |
work_keys_str_mv | AT liufrankxiaoqing patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT wittedwarda patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT ebbinghausscot patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT dibonaventurabeyergrace patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT shindereshma patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT basurtoenrique patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT josephrichardw patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment |